Related Experiment Video

Updated: May 7, 2026

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii
09:17

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii

Published on: January 2, 2017

17.4K

Understanding the pharmacokinetics of tulathromycin: a pulmonary perspective

N Villarino1, S A Brown, T Martín-Jiménez

  • 1Department of Microbiology, College of Arts and Sciences, University of Tennessee, Knoxville, TN, USA.

Journal of Veterinary Pharmacology and Therapeutics
|October 15, 2013
PubMed

Insights

Tulathromycin, a macrolide antibiotic, is effective for treating bovine and swine respiratory diseases. It concentrates in lung tissue and inflammatory cells, offering prolonged intra-airway presence after a single dose.

Area of Science:

  • Veterinary Pharmacology
  • Antimicrobial Pharmacokinetics
  • Macrolide Antibiotics

Background:

  • Tulathromycin is approved for treating respiratory diseases in cattle and swine.
  • It is also indicated for infectious bovine keratoconjunctivitis and bovine interdigital necrobacillosis.
  • Macrolides are known for their ability to concentrate in specific tissues.

Purpose of the Study:

  • To review the pharmacokinetic properties of tulathromycin.
  • To emphasize tulathromycin's behavior within the respiratory system.
  • To consolidate pharmacokinetic data across various veterinary species.

Main Methods:

  • Literature review of pharmacokinetic studies on tulathromycin.
  • Analysis of drug distribution and persistence in target tissues.
  • Examination of tulathromycin accumulation in immune cells.

Main Results:

  • Tulathromycin exhibits high concentration in lung tissue.
  • The drug persists in the intra-airway compartment for an extended period post-administration.
  • Tulathromycin accumulates in inflammatory cells like neutrophils and macrophages.

Conclusions:

  • Tulathromycin's pharmacokinetic profile supports its efficacy in respiratory tract infections.
  • Its concentration in lung tissue and inflammatory cells contributes to sustained therapeutic levels.
  • Understanding these pharmacokinetics is crucial for optimizing tulathromycin use in veterinary medicine.

More Related Videos

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS08:38

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS

Published on: November 8, 2015

16.2K
A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis10:29

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis

Published on: March 24, 2017

7.4K

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
414
Pharmacodynamic Models: Overview01:27

Pharmacodynamic Models: Overview

Pharmacodynamic (PD) responses describe the interaction between a drug and its biological target, culminating in a physiological effect. These responses can be classified into different types: continuous variables, such as blood glucose levels; categorical outcomes, like survival rates; and time-to-event metrics, such as disease progression. Understanding and modeling PD responses are critical for optimizing drug efficacy and safety.PD models describe the relationship between drug concentration...
163
Pharmacokinetic–Pharmacodynamic Relationship: Influence of Elimination Half-Life on Effect Duration01:23

Pharmacokinetic–Pharmacodynamic Relationship: Influence of Elimination Half-Life on Effect Duration

Drug elimination from the body primarily occurs through metabolic and excretion pathways. Hepatic metabolism transforms lipophilic drugs into hydrophilic forms for excretion, typically via enzymatic processes classified as phase I (modification) and phase II (conjugation). Renal excretion eliminates drugs and metabolites through filtration and secretion in the kidneys. Impairment in liver or kidney function can hinder these processes, delaying drug clearance and extending the drug’s...
145
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
982
Pharmacokinetics: Overview01:10

Pharmacokinetics: Overview

Pharmacokinetics is a scientific discipline that focuses on the journey of a drug within the body, encompassing four key stages: absorption, distribution, metabolism, and elimination. The first stage, absorption, involves the drug's transfer into the bloodstream. Several factors dictate the extent and speed of this process. For example, the liver often metabolizes oral drugs before they reach systemic circulation, leading to only partial absorption. In contrast, intravenous (IV)...
9.9K
Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
1.0K